DiaMedica Therapeutics Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
DiaMedica (DMAC) reported positive topline results from its Phase 2 late-onset preeclampsia Part 1a dose-extension cohort, showing statistically significant reductions in maternal blood pressure (29.1 mmHg systolic, 17.0 mmHg diastolic; p<0.001). The company completed enrollment of the first cohort (6 patients) in its early-onset fetal growth restriction Phase 2 trial and is progressing the ReMEDy2 acute ischemic stroke Phase 2/3 trial (85% enrolled toward 200-patient interim analysis expected Q1 2027). Cash position of $43.5M as of June 30, 2026 provides runway through 2027; net loss was $20.2M for H1 2026 (vs. $15.4M H1 2025); operating cash burn accelerated to $17.2M H1 2026 (vs. $14.7M H1 2025).
Why this rating
Positive clinical efficacy data and trial progress support pipeline advancement for ~$96M company. Meaningful cash burn (18% of market cap in 6 months) against $43.5M runway creates moderate near-term pressure; clinical validation offsets financial headwind.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.